氟替美维吸入粉雾剂(Trelegy Ellipta)的功效与作用

Flutimavir inhalation powder spray (TrelegyEllipta) is a triple compound inhalation powder spray, used for long-term maintenance treatment of chronic obstructive pulmonary disease and asthma.

Efficacy and effects of flutimevir inhalation powder spray (Trelegy Ellipta)

It is a combination preparation of fluticasone furoate (an inhaled corticosteroid, ICS), umeclidinium bromide (an anticholinergic drug) and vilanterol (a long-acting β2-adrenoceptor agonist, LABA). It is suitable for:

1. Maintenance treatment of patients with chronic obstructive pulmonary disease.

2. Maintenance treatment for asthma patients aged 18 and above.

Restrictions on use: Not indicated for the relief of acute bronchospasm.

Dosage and administration method of Flutimavir Inhalation Powder Aerosol (Trelegy Ellipta)

1. Maintenance treatment of COPD

Administer via oral inhalation once a day, with one puff of Flutimavir Inhalation Powder Aerosol 100/62.5/25 micrograms per inhalation.

2. Maintenance treatment of asthma

Administer via oral inhalation once a day, with each inhalation of flutimavir inhalation powder spray 100/62.5/25 micrograms or one puff of flutimavir inhalation powder spray 200/62.5/25 micrograms.

The pictures are from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Contraindications of flutimavir inhalation powder (Trelegy Ellipta)

1. It is contraindicated as the primary treatment for status asthmaticus or acute exacerbation of chronic obstructive pulmonary disease or asthma that requires intensive measures.

2. It is prohibited for those with a history of severe allergies to milk protein or any ingredients.

Precautions for flutimavir inhalation powder (Trelegy Ellipta)

1. Use of LABA monotherapy alone will increase the risk of severe asthma-related events.

2. Candida albicans infection of the oral cavity and pharynx may occur, and patients should be monitored regularly. Advise patients to rinse their mouth with water after inhalation (do not swallow) to help reduce risk.

3. Patients with chronic obstructive pulmonary disease are at increased risk of developing pneumonia. Monitor patients for signs and symptoms of pneumonia.

4. Long-term use of ICS may cause glaucoma and cataracts. May worsen narrow-angle glaucoma. Use with caution in patients with narrow-angle glaucoma and instruct patients to contact their healthcare provider immediately if symptoms occur. Referral to an ophthalmologist should be considered in patients who develop ocular symptoms or who are taking TRELEGYELLIPTA for a long period of time.

5. It may worsen urinary retention. It should be used with caution in patients with prostatic hyperplasia or bladder neck obstruction, and patients should be instructed to contact medical staff immediately if symptoms occur.

6. It should be used with caution in patients with convulsive disorders, thyrotoxicosis, diabetic mellitus and ketoacidosis.

Adverse reactions of flutimavir inhalation powder (Trelegy Ellipta)

1. Used for chronic obstructive pulmonary disease

The most common adverse reactions (incidence ≥1% ) includes upper respiratory tract infection, pneumonia, bronchitis, oral candidiasis, headache, back pain, joint pain, influenza, sinusitis, pharyngitis, rhinitis, dysgeusia, constipation, urinary tract infection, diarrhea, gastroenteritis, oropharyngeal pain, cough and dysphonia.

2. For asthma

The most common adverse reactions (incidence ≥2%) include pharyngitis/nasopharyngitis, upper respiratory tract infection/viral upper respiratory tract infection, bronchitis, respiratory tract infection/viral respiratory tract infection, sinusitis/acute sinusitis, urinary tract infection, rhinitis, influenza, headache and back pain.